Something seems to be happening with GDNF(and its not about the long delayed NIH trial). Received a Google Alert , stating that MedGenesis, a small biotech in BC, Canada raised 5 million for phase 2 GDNF Trials.The company obtained the rights to Amgen's gdnf protein in 2010, and they are working on delivering this protein to the brain by Convection Enhanced Delivery. This is not gene therapy.
see:

http://news.techfinance.ca/medgenesi...-of-financing/

They are planning to start a phase II trial.
Excerpt:
"“This financing will assist us in the completion of the phase II clinical program for GDNF and allows us to now shift our focus to financing our Phase III program, including the development of pharmaceutical company partnerships,” said Dr. Erich Mohr, Chairman & CEO of MedGenesis Therapeutix. “We are hopeful that this potentially disease-modifying treatment will significantly change the quality of life of patients with Parkinson’s Disease as well as have applications in other neurological indications.”"

See also:
http://www.terrapinn.com/exhibition/...peutix-inc.stm

And an interview with cEO Eric Mohr from 2010
http://biotuesdays.com/2010/04/13/in...th-erich-mohr/

In 2010 the sponsor received a MJFF grant
http://www.michaeljfox.org/research_...s_3.cfm?ID=664

Also see Medgenesis web site
http://www.medgenesis.com/index.htm